ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov ID: NCT06790966

Public ClinicalTrials.gov record NCT06790966. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-Line Treatment of Unresectable Recurrent and/or Metastatic HPV16+ Head and Neck Squamous Cell Carcinoma

Study identification

NCT ID
NCT06790966
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
PDS Biotechnology Corp.
Industry
Enrollment
252 participants

Conditions and interventions

Interventions

  • Combination Treatment of PDS0101 and Pembrolizumab Combination Product
  • Pembrolizumab Monotherapy Drug

Combination Product · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 29, 2025
Primary completion
Jan 31, 2029
Completion
Jan 31, 2029
Last update posted
Apr 5, 2026

2025 – 2029

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
27
Facility City State ZIP Site status
Mayo Clinic Arizona Phoenix Arizona 85054
Marin Cancer Care Greenbrae California 94904
University of California, Orange Orange California 92686
Yale University New Haven Connecticut 06510
Mayo Clinic Florida Jacksonville Florida 32224
Florida Cancer Affiliates - Ocala Oncology Ocala Florida 34474
SCRI - Florida Cancer Specialists Orlando Florida 32827
Emory University - Winship Cancer Institute (WCI) Atlanta Georgia 30322
University of Kansas Westwood Kansas 66205
University of Kentucky Lexington Kentucky 40536
Norton Cancer Institute Louisville Kentucky 40202
University of Louisville Louisville Kentucky 40202
University of Maryland Baltimore Maryland 21201
University of Michigan Ann Arbor Michigan 48109
Karmanos Cancer Institute Detroit Michigan 48201
Mayo Clinic Rochester Rochester Minnesota 55905
University of North Carolina Chapel Hill North Carolina 27599-7025
The Ohio State University- James Cancer Hospital Columbus Ohio 43210
Penn State Health Hershey Pennsylvania 17033
Fox Chase Cancer Center Philadelphia Pennsylvania 19103
Medical University of South Carolina Charleston South Carolina 29407
University of Tennessee Medical Center Knoxville Tennessee 37920
Texas Oncology Austin Texas 78705
UT Health San Antonio San Antonio Texas 78229
Texas Oncology-Northeast Texas Tyler Texas 75702
University of Virginia Health System Charlottesville Virginia 22903
Virginia Oncology Associates Norfolk Virginia 23502
West Virginia University Cancer Center Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06790966, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 5, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06790966 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →